PARK MEDI WORLD LIMITED (PARKHOSPS) Fair Value & Analysis
Healthcare · IN · Market cap ₹124B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹116.50 to ₹130.24 (+11.8%) since Aug 8, 2026. Share price +1.0% over the past month.
A solid business, but screening 53% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹164.34). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹72.17 to ₹164.34) leaves room in how you read the outcome.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
8‑month range ₹143.92 – ₹299.30 · fair‑value band ₹72.17 – ₹164.34 · the ₹276.65 price screens above the ₹130.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Aug 13, 2026.
Analysis
PARK MEDI WORLD LIMITED (PARKHOSPS) currently trades at ₹276.65, while our model-based Fair Value estimate is ₹130.24, implying the stock looks roughly 52.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PARK MEDI WORLD LIMITED generated revenue of ₹16.8B at a net margin of 15.4%. Revenue grew 30.1% year over year. It earns a return on equity of 16.9%. Net debt stands at ₹5.2B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹72.17 (bear case) to ₹164.34 (bull case); at ₹276.65, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 100% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -53%, PARKHOSPS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹148.91) versus Asset-Based (₹31.36). Highest evidence: Growth DCF (80).
Notify me when PARKHOSPS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 70
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone …
Full company description
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
PARK MEDI WORLD LIMITED reported revenue of ₹16.8B in FY2026 versus ₹12.5B in FY2023, a compound +10.3%/yr. Reported net income was ₹2.6B in FY2026, compounding +5.5%/yr from FY2023.
PARKHOSPS screens 53% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare PARK MEDI WORLD LIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PARK MEDI WORLD LIMITED (PARKHOSPS) overvalued or undervalued?
What is the fair value of PARKHOSPS?
What is the quality score of PARKHOSPS?
What is the revenue of PARK MEDI WORLD LIMITED (PARKHOSPS)?
What is the net profit margin of PARKHOSPS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PARK MEDI WORLD LIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.